Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011

Pancreatic adenocarcinoma has repetitively proved refractory to chemotherapy and biologic compounds with only a few drugs offering limited benefit. A number of novel regimens has been tested in phase I trials and reported recently in the 2011 American Society of Clinical Oncology (ASCO) Gastrointest...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Dimou, Anastasios T, Syrigos, Konstantinos N, Saif, Muhammad Wasif
Format:	Tagungsbericht
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Anticoagulants - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Trials, Phase I as Topic Connective Tissue Growth Factor - immunology Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Enzyme Inhibitors - administration & dosage Factor VIIa - antagonists & inhibitors Factor VIIa - metabolism Humans MAP Kinase Kinase 1 - antagonists & inhibitors MAP Kinase Kinase 1 - metabolism MAP Kinase Kinase 2 - antagonists & inhibitors MAP Kinase Kinase 2 - metabolism Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Pyridones - administration & dosage Pyrimidinones - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pancreatic adenocarcinoma has repetitively proved refractory to chemotherapy and biologic compounds with only a few drugs offering limited benefit. A number of novel regimens has been tested in phase I trials and reported recently in the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Specifically, a novel mitogen-activated protein kinase kinase (MEK) inhibitor, a connective tissue growth factor inhibitor, a coagulase factor VIIa inhibitor, as well as adenovirus delivery of herpes simplex virus thymidine synthase gene followed by anti-herpetic treatment have all proven to be safe in pancreatic cancer patients. Phase II trials will provide further evidence whether they can become clinically relevant in the future.
ISSN:	1590-8577